HANALL BIOPHARMA CO.,LTD
Biopharmaceutical firm focused on immunology, ophthalmology, and immuno-oncology.
009420 | KO
Overview
Corporate Details
- ISIN(s):
- KR7009420001
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 대덕구 상서당1길 43, 대전광역시
- Website:
- http://www.hanallbiopharma.com/
- Sector:
- Manufacturing
Description
HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-19 00:00 |
투자판단관련주요경영사항
|
Korean | 12.2 KB | ||
| 2023-05-15 00:00 |
분기보고서 (2023.03)
|
Korean | 1.4 MB | ||
| 2023-04-28 00:00 |
영업(잠정)실적(공정공시)
|
Korean | 14.0 KB | ||
| 2023-03-29 00:00 |
정기주주총회결과
|
Korean | 27.6 KB | ||
| 2023-03-29 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 8.4 KB | ||
| 2023-03-29 00:00 |
주식매수선택권부여에관한신고
|
Korean | 13.2 KB | ||
| 2023-03-29 00:00 |
대표이사(대표집행임원)변경(안내공시)
|
Korean | 5.9 KB | ||
| 2023-03-21 00:00 |
사업보고서 (2022.12)
|
Korean | 1.7 MB | ||
| 2023-03-14 00:00 |
주주총회소집공고
|
Korean | 1.0 MB | ||
| 2023-03-10 00:00 |
주주총회소집결의
|
Korean | 15.2 KB | ||
| 2023-03-06 00:00 |
감사보고서제출
|
Korean | 18.5 KB | ||
| 2023-01-19 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 14.0 KB | ||
| 2023-01-19 00:00 |
영업(잠정)실적(공정공시)
|
Korean | 14.0 KB | ||
| 2023-01-03 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 63.9 KB | ||
| 2022-12-08 00:00 |
투자판단관련주요경영사항(HL161 관련 마일스톤 기술료 수령)
|
Korean | 7.3 KB |
Automate Your Workflow. Get a real-time feed of all HANALL BIOPHARMA CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for HANALL BIOPHARMA CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HANALL BIOPHARMA CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
